Conclusions: Aortic neck diameter increases consistently over time following EVAR. The degree of neck dilatation correlates with degree of device oversize but not with device type.
Summary: Implications of aortic neck dilatation following endovascular aneurysm repair (EVAR) are unclear. Previous studies are limited to comparisons of individual, early generation devices. The authors' compared aortic neck dilatation among contemporary stent grafts in this retrospective study of a prospectively maintained single center database. They reviewed preoperative and postoperative computed tomographic angiograms (at least one > 6 months after implant) for elective EVARs performed from [2008] [2009] [2010] [2011] [2012] [2013] [2014] . Images were analyzed using three-dimensional centerline reconstructions. Aortic neck diameter was measured in orthogonal planes at and 10mm below the lowest renal artery. Device type and main body graft diameter were obtained from operative reports. Eighty-six patients were analyzed with a median radiologic follow-up of 21.9 months (range, 4-64 months) and 81.3% had imaging at one year. The cohort was predominantly male (86.1%) with a mean age of 75.6 years (range, 60-94 years) and comorbidities were notable for significant coronary disease (50.0%) and smoking history (76.7%). Stent grants implanted included 26 Cook Zenith, 26 Gore Excluder, 22 Medtronic Endurant, 10 Endologix Powerlink, and 2 Trivascular Ovation devices. Mean device oversizing was 13.6 6 11.5% and did not vary by device type (P ¼ .54). Most patients (86.0%) experienced increases in aortic neck diameter during follow-up, with a mean increase of 1.3 6 2.2 mm (5.9 6 9.3 %) and 3.3 6 0.6 mm (8.9 6 2.5%) at 30 day and at latest follow-up scans, respectively. Repeated-measures analysis further demonstrated a significant increase in mean neck dilatation during follow-up (P < .001). Neck dilatation was not significantly different across different devices (P ¼ .233). However, there was a moderate positive correlation between percent change in neck diameter and degree of oversizing, which was statistically significant (P < .001). Type IA endoleak was observed in two patients and was associated with greater mean neck dilatation (8.8 6 3.3 mm vs 3.35 6 2.71; P ¼ .041). There was no relationship between changes in neck diameter and sac regression/expansion.
Comments: This study demonstrates infrarenal aortic neck dilation after endograft repair, which is progressive over time and associated with endograft oversizing. Whether this is due to the radial force the device uses to secure water tight seal, which then ceases when this force vector reaches equilibrium as some studies suggest, or to progressive aneurysmal growth is still not completely understood. The latter event would, of course, be unfortunate since a wave of type IA endoleaks would be expected that fortunately has not be observed in current experience. This study would confirm this lack of clinical consequence but lacks longterm follow-up. A similar focus was reported in the Journal of Vascular Surgery but at 24 months there was a negative clinical impact with a higher risk of type IA endoleaks observed at 24 months. 1 Much is yet to be learned regarding endograft repair of infrarenal abdominal aortic aneurysms in the long-term that being 10-15 years. Summary: Real-world contemporary date on trends in rates and outcomes of carotid endarterectomy and carotid artery stenting are limited. The goal of this study is to describe US national trends in performance and outcomes of isolated carotid endarterectomy or stenting among Medicare beneficiaries from 1999 to 2014 (16 years) and was accomplished by serial cross-sectional analysis of Medicare fee-for-service beneficiaries aged 65 years or older using the Medicare Inpatient and Denominator files. Spatial mixed models adjusted for age, sex, and race were fit to calculate county-specific risk-standardized revascularization rates. Mixed models were fit to assess trends in outcomes after adjustment for demographics, comorbidities, and symptomatic status. The major outcomes were revascularization rates per 100 000 beneficiaryyears of fee-for-service enrollment, in-hospital mortality, 30-day stroke or death, 30-day stroke, myocardial infarction, or death, 30-day all-cause mortality, and 1-year stroke. During the study; 937,111 unique patients underwent carotid endarterectomy (mean age, 75.8 years; 43% women) and 231,077 underwent carotid artery stenting (mean age, 75.4 years; 49% women). There were 81,306 patients who underwent endarterectomy in 1999 and 36,325 in 2014; national rates per 100 000 beneficiaryyears decreased from 298 in 1999-2000 to 128 in 2013-2014 (P < .001). The number of patients who underwent stenting ranged from 10,416 in 1999 to 22,865 in 2006 (an increase per 100 000 beneficiary-years from 40 in 1999-2000 to 75 in 2005-2006; P < 0.001); by 2014, there were 10,208 patients who underwent stenting and the rate decreased to 38 per 100,000 beneficiary-years (P < .001). County specific variations were noted with higher rates for both procedures in central and southern regions that did not change over time. For both procedures, there was an increase in the proportion of symptomatic patients over time (P < .001). For example in those undergoing a carotid artery stenting, the percentage of symptomatic patients varied from 14.4% in 1999-2000 to 25.9% in 2013-2014. Outcomes improved over time despite increases in vascular risk factors (all factors: P < .001). The composite of ischemic stroke or death decreased from 4.4% in 1999-2000 to 3.1% in 2013-2014 for carotid endarterectomy and from 7.0% to 4.8% between 1999-2000 and 2005-2006 and then increased to 7.0% by 2013-2014 for carotid artery stenting. There were adjusted annual decreases in 30-day ischemic stroke or death of 2.90% (95% confidence interval [CI], 2.63%-3.18%) among patients who underwent endarterectomy and 1.13% (95% CI, 0.71%-1.54%) among patients who underwent stenting; an absolute decrease from 1999 to 2014 was observed for endarterectomy (1.4%; 95% CI, 1.2%-1.5%) but not stenting (À0.1%; 95% CI, À 0.5% to 0.4%). Rates for 1-year ischemic stroke decreased after endarterectomy (absolute decrease, 3.5%; 95% CI, 3.2%-3.7%; adjusted annual decrease, 2.17%; 95% CI, 2.00%-2.34%) and stenting (absolute decrease, 1.6%; 95% CI, 1.2%-2.1%; adjusted annual decrease, 1.86%; 95% CI, 1.45%-2.26%). Additional improvements were noted for in-hospital mortality, 30-day stroke, myocardial infarction, or death, and 30-day all-cause mortality as well as within demographic subgroups. The index median hospital stay decreased from 2 to 1 day for each procedure while cost decreased for carotid endarterectomy to $6779 while that for carotid artery stenting increased to $14796.
Comments: The scrutiny of carotid procedures has been evident since the early 1980's and has continued/intensified since that time while the medical management of atherosclerosis has improved both likely leading to improvements in interventional results. The decrease in carotid artery stenting procedures reflects a restriction to reimbursement in the Medicare population. Interestingly, there are still a high percentage of asymptomatic patients undergoing carotid artery stenting during a time when reimbursement outside of a study is curtailed. In the final analysis, this "big data" study confirms that carotid artery stenting has higher 30-day risks and cost, which likely influences decisions made by Medicare regarding reimbursement.
Use of Resuscitative Endovascular Balloon
Occlusion of the Aorta for Proximal Aortic Control in Patients With Severe Hemorrhage and Arrest more targeted aortic occlusion (AO) in the distal aorta for pelvic, junctional, or extremity hemorrhage.
Summary: This study describes the current largest single-institution experience with REBOA in the United States. The use of REBOA at an urban tertiary care facility for severe traumatic hemorrhage, traumatic arrest (AR), or nontraumatic hemorrhage (NTH) was investigated from February 1, 2013 to January 31, 2017, among 90 patients who were not responsive or were transiently responsive to resuscitation measures, or were in arrest, from presumed hemorrhage below the diaphragm. Possible causes were trauma or nontrauma-related hemorrhage. Patients with ruptured aortic aneurysms were excluded. The main outcome was in-hospital mortality. Approximately 20% of the procedures were performed by endovascular trained vascular surgeons while the rest by acute care surgeons without formal endovascular training. Seventeen percent were malpositioned as noted by some type of imaging and required more proximal positioning. Of the 90 patients in the study (15 women and 75 men; mean [SD] age, 41.5 [17.4] years), 29 underwent REBOA for severe traumatic hemorrhage, 50 for AR, and 11 for NTH. For the patients with severe traumatic hemorrhage and AR, the median age was 36.2 years (interquartile range, 25.3-55.5 years), mean (SD) admission Glasgow Coma Scale score was 6 (5), and median Injury Severity Score was 39 (interquartile range, 10-75). The distal thoracic aorta was occluded in 73 patients (81%), and in all patients with AR. A total of 17 patients (19%) had distal abdominal AO. Mean (SD) systolic blood pressure improved in patients with severe traumatic hemorrhage, from 68 (28) mmHg prior to AO, to 131 (12) mmHg after AO (P < 0.001). Percutaneous access was used in 30 patients (33%), including 13 patients with AR (26%), and groin cutdown in 60 patients (67%), including 37 patients with AR (74%). Overall 30-day mortality was 62% (n ¼ 56): 11 (39%) in patients with severe traumatic hemorrhage and 45 (90%) in patients with AR. Of the patients with AR, 29 (58%) had return of spontaneous circulation and 11 of those patients (38%) survived to the operating room. All patients who survived AR gained full neurologic recovery. No aortoiliac injury or limb loss occurred from REBOA use per se but rather from severe preplacement extremity injury. Eleven patients underwent REBOA for NTH; 7 (64%) were in arrest. Overall in-hospital mortality for patients with NTH was 36% (n ¼ 4). Only patient died of bowel necrosis after an inflation time of longer than 2 hours. No procedural complications occurred in this group but at the time of removal three access site repairs were required in addition to 9 patients who required thrombectomy, 6 of whom were cannulated with 12 French sheaths.
Comments: Others are learning from our experience with the care of a ruptured abdominal aortic aneurysm. This experience confirms in another cohort of patients the utility of aortic balloon occlusion for control of significant abdominal arterial bleeding with some risk of malposition without immediate imaging. Access site repair or extremity thrombectomy is not uncommon, may be the price for a survival advantage, but most be considered to prevent delayed morbidity or mortality. Conclusions: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo.
Effects of Anacetrapib in Patients With
Summary: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or even adverse effects on cardiovascular outcomes. In this industrial sponsored randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter, a mean non-HDL cholesterol level of 92 mg per deciliter, and a mean HDL cholesterol level of 40 mg per deciliter. The authors have classified it as the phase 3 Randomized Evaluation of the Effects of Anacetrapib through Lipid Modification (REVEAL) trial. Routine follow-up was at 2 months than 6 months until study's end. The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. Secondary outcomes were major atherosclerotic events (a composite of coronary death, myocardial infarction, or presumed ischemic stroke), presumed ischemic stroke (ie, not known to be hemorrhagic), and major vascular events (a composite of major coronary events or presumed ischemic stroke). During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P ¼ 0.004). The relative difference in risk was similar across multiple pre-specified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (a relative difference of À18%).The only secondary outcome not statistically different was the effect of anacetrapib on presumed ischemic stroke (rate ratio, 0.99; 95% confidence interval, 0.87-1.12).There were no significant between group differences in the risk of death, cancer, or other serious adverse events.
Comments: Aggressive lowering of LDL serum levels has an incremental reduction in the risk of major cardiovascular events which appears to be augmented by the use of this particular CETP inhibitor. Several other studies of similar drugs have either been stopped early or did not improve the prevention rate of cardiovascular events over time. The authors' feel that this study differs in terms of the number of patients involved, stringent LDL level maintenance and length of treatment in addition to the specific attributes of anacetrapib. Fortunately, side-effects of this agent do not appear substantial but since it is stored in adipose tissues (with slow egress) the longer term side effects may yet to be determined. Conclusions: Hospital participation in the VQI registry by itself does not increase rates of surveillance imaging after vascular procedures, suggesting that other strategies are needed to achieve this quality metric.
Association of Quality Improvement Registry
Summary: Ensuring that patients undergo surveillance imaging after surgery is a key to improving long term results after many vascular procedures. It is unclear whether hospital participation in a national quality improvement registry such as the Vascular Quality Initiative (VQI) achieves this goal. This study was undertaken to determine if hospital participation in the VQI registry is associated with increased rates of surveillance imaging after vascular procedures. A quasi-experimental study used Medicare claims to study 2174 US hospitals in which 1,530,102 patients had undergone an endovascular abdominal aortic aneurysm repair (EVAR); 1,403,067 patients had undergone a lower extremity bypass (LEB) or peripheral vascular intervention (PVI), and 294,942 patients had undergone carotid endarterectomy (CEA) and carotid artery stenting (CAS) procedures over a 6 year period ending in 2012. For each hospital, VQI participation was assessed, and a difference-in-differences analysis was used to measure the change in follow-up surveillance for VQI hospitals compared with control (non-VQI) hospitals selected after propensity score matching. The data were analyzed between January and August of 2016. The primary outcome was the proportion of patients who had imaging-based follow-up (computed tomography, duplex ultrasonography, or ankle-brachial index) within 1 year after their vascular procedure. A total of 1,830 928 patients (947,139 women and 883,789 men; mean age (standard deviation [SD]) 75.8 [7.1] years) were identified across 2174 hospitals. Of 3,228,111 total vascular procedures, 1,403,067 patients (43.5%) underwent LEB or PVI, 1,530,102 patients (47.4%) underwent EVAR, and 294,942 patients (9.1%) underwent CEA or CAS. During the 6-year period, follow-up imaging rates varied between 50% and 53% after EVAR, between 52%and 58% after LEB or PVI, and between 74%and 78% after CEA or CAS. A total of 68 VQI participating hospitals were propensity-matched to 68 control hospitals, and 279.446 patients were studied across these 136 hospitals. In difference-in-differences analyses, there was no significant improvement in follow-up imaging after joining VQI during year 1 (relative risk, 0.99; 95% confidence interval [CI], 0.97-1.01),
